Nicholas Maragakis treats patients with motor neuron diseases, such as amyotrophic lateral sclerosis (ALS). This care is coordinated with the Johns Hopkins Center for ALS Specialty Care, a multidisciplinary clinic with expertise in treating patients with ALS and providing support to their caregivers. He serves as medical director of the ALS Clinical Trials Unit, an extension of the multidisciplinary clinic that seeks to facilitate opportunities for patients with ALS to participate in clinical trials that could advance the treatment of this disease. Dr. Maragakis is interested in the basic science of understanding neurodegenerative diseases, as well as the translational potential of therapeutic compounds developed in the laboratory. His fundamental research interest is in using stem cells — more specifically, stem cell-derived motor neurons and glia — for understanding the development and propagation of ALS. His laboratory has been involved in creating and characterizing lines of stem cells from patients with ALS using induced pluripotent stem cell (iPSC) methodologies. The laboratory has a large library of iPSCs from patients with familial ALS and from patients with sporadic ALS. The utilization of this library of iPSCs has facilitated the development of a spinal cord-specific iPSC-astrocyte/motor neuron co-culture system, which has been leveraged for the development of assays that can be used for both the basic understanding of ALS astrocyte and motor neuron biology as well as, eventually, drug screening for ALS therapeutics. His laboratory has taken its long-standing interests in astrocyte biology, as it relates to ALS, to develop a program that investigates astrocyte-specific mechanisms as contributors to the progression (both temporally and anatomically) of disease in ALS. In this vein, there is an interest in astrocytic glutamate transporters and, more recently, astrocyte hemichannels and gap junctions. Dr. Maragakis is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, 15q11.2 Microdeletion, and Spinal Muscular Atrophy (SMA).

Bryan Traynor is a Neurologist in Baltimore, Maryland. Dr. Traynor is rated as an Elite provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Frontotemporal Dementia, Dementia, and Thymectomy.

Dr. Brett Morrison specializes in neuromuscular disorders in adults including peripheral neuropathies, amyotrophic lateral sclerosis, myasthenia gravis and muscle diseases. Dr. Morrison is currently the site principal investigator for clinical trials investigating new treatments for chronic inflammatory demyelinating polyneuropathy (CIDP) and painful diabetic peripheral neuropathy. Dr. Morrison's research interests include investigations into the mechanisms of nerve regeneration and common peripheral neuropathies. Current research focuses on better understanding the role of the immune system in peripheral nerves and targeting these pathways for the development of new treatments. Dr. Brett Morrison received his M.D. and Ph.D. from Mount Sinai Medical School in New York City. He completed his medical internship at the University of Maryland and residency in neurology at The Johns Hopkins Hospital. He then completed a fellowship in Clinical Neurophysiology at The Johns Hopkins Hospital. Dr. Morrison is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Spinal Muscular Atrophy (SMA).

Dr. Jeffrey Rothstein focuses on neuromuscular diseases, with a particular focus on Amyotrophic lateral sclerosis (ALS). Other clinical areas relevant to his laboratory-based research include idiopathic stupor, epilepsy, and motor neuron degeneration. His laboratory includes more than 25 post-doctoral fellows, neurology residents, neuromuscular fellows, junior faculty, undergraduate students, technicians, and ALS clinic staff. He has been the principal and/or local investigator in more than 20 national or international trials in ALS. He is the author of more than 360 articles on basic and clinical neuroscience. Dr. Rothstein's laboratory research is funded through the National Institutes of Health, the Dept of Defense, Target ALS, Maryland TEDCO, Alzheimer's Drug Discovery Foundation, the Muscular Dystrophy Association, the ALS Association, and Answer ALS. Dr. Jeffrey Rothstein received a masters degree in neurochemistry from the University of Chicago and a Ph.D. in physiology and biophysics from the University of Illinois Health Sciences Center. He then obtained his medical degree from the University of Illinois College of Medicine. He went on to complete an internship at the University of North Carolina Memorial Hospital before joining The Johns Hopkins for his residency. While at Johns Hopkins, he became chief resident in neurology and completed his fellowship in neuromuscular disease. He has been Professor of Neurology and Neuroscience at Johns Hopkins for more than 25 years. Dr. Rothstein is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Spinal Muscular Atrophy Type 3.

Neurologist Payam Mohassel specializes in myopathies, muscular dystrophies, and other hereditary neuromuscular disorders and is the co-director of the Johns Hopkins Myositis Center. Dr. Mohassel obtained his medical degree from the Johns Hopkins University School of Medicine, where he remained for a medical internship, residency training in neurology, and clinical fellowship training in neuromuscular medicine. He then joined the National Institute of Neurological Disorders and Stroke Neurogenetics branch as a clinical research fellow. Dr. Mohassel’s research focuses on translational studies on neuromuscular disorders, and it spans gene discovery efforts, mechanistic studies to identify therapeutic targets, and early phase interventional clinical trials. Dr. Mohassel is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Hereditary Sensory Neuropathy Type 1 (HSN1), and Hereditary Sensory and Autonomic Neuropathy Type 2.

Dr. Nathan Crone focuses on the diagnosis and treatment of seizures and epilepsy, including the surgical treatment of epilepsy. He is also one of the attending physicians in the Epilepsy monitoring unit. Dr. Crone''s research interests include the real-time mapping of brain function to reduce the possibility of impacting brain function during surgery for epilepsy. He received his medical degree from Louisiana State University School of Medicine. He then completed his residency in neurology at the University of Chicago and fellowships in epilepsy and cognitive neurology at Johns Hopkins. Dr. Crone is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Deep Brain Stimulation.

Dr. Scholz is a neurologist and geneticist specializing in neurodegenerative disorders such as Parkinson's disease, atypical parkinsonism and dementia syndromes. She received her medical degree from the Medical University Innsbruck, Austria. Following graduation, she was a postdoctoral fellow at the National Institutes of Health under the supervision of Drs. Andrew Singleton and John Hardy. She obtained a Ph.D. in neurogenomics from the University College London, UK in 2010. She then moved to Baltimore to complete her neurology residency training at Johns Hopkins. In 2015 Dr. Scholz received the McFarland Transition to Independence Award for Neurologist-Scientists. She is Lasker Clinical Research Scholar at the National Institute of Neurological Disorders and Stroke focusing on genetic causes of neurodegenerative syndromes, and an adjunct faculty member at Johns Hopkins' department of neurology. Dr. Scholz is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her top areas of expertise are Lewy Body Dementia (LBD), Multiple System Atrophy, Movement Disorders, and Parkinson's Disease.

James Russell is a Neurologist in Baltimore, Maryland. Dr. Russell is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Cramp-Fasciculation Syndrome, Peripheral Neuropathy, and Thyroidectomy.

Chandana Chauhan is a Neurologist in Baltimore, Maryland. Dr. Chauhan is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy (SMA), and Spinal Muscular Atrophy Type 3.

Vinay Chaudhry is a Neurologist in Baltimore, Maryland. Dr. Chaudhry is rated as a Distinguished provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Myasthenia Gravis, Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Advanced Bronchoscopy.

Arens Taga is a neurologist specializing in neuromuscular diseases, with a particular focus on amyotrophic lateral sclerosis (ALS) and other motor neuron diseases. His clinical work aims to improve the quality of care for patients with ALS through biomarker-based, precision medicine approaches that refine disease stratification and facilitate more targeted and efficient enrollment in clinical trials. As a clinician-scientist, Dr. Taga uses patient-derived induced pluripotent stem cells to model ALS, uncover novel disease mechanisms and identify therapeutic targets that are translatable to clinical trials. In recognition of his work in ALS, Dr. Taga was awarded the 2025 Richard Olney Clinician Scientist Development Award, which honors early-career physician-scientists dedicated to advancing ALS research. Dr. Taga earned his medical degree from the School of Medicine and Surgery at the University of Parma, Italy, where he also completed his neurology residency. He subsequently trained at The Johns Hopkins University, completing a postdoctoral research fellowship in the neuromuscular division, an internal medicine internship, a neurology residency and a neuromuscular clinical fellowship. Dr. Taga is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are 15q11.2 Microdeletion, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Cluster Headache.

Dr. Ahmet Hoke is Professor of Neurology and Neuroscience, W. W. Smith Charitable Trust Professor of Neuroimmunology at Johns Hopkins School of Medicine, Director of the Daniel B. Drachman Division of Neuromuscular Diseases and Director of the Merkin Peripheral Neuropathy and Nerve Regeneration Center at Johns Hopkins University School of Medicine. He completed his medical training at Hacettepe University School of Medicine in Ankara, Turkey followed by his PhD studies in developmental neuroscience at Case Western Reserve University in Cleveland, Ohio, and neurology residency at Johns Hopkins Hospital. After completing his neuromuscular training at University of Calgary, Canada, he returned to Johns Hopkins University as faculty and rose through the ranks. He is the recipient of several awards including Derek Denny Brown Young Neurological Scholar Award (2005) and Wolfe Neuropathy Research prize (2018) given by the American Neurological Association, Myung Memorial Lecture Award (2017) by the Korean Neurological Association, Nejat Eczacibasi Medical Scientist Award (2019) by the Eczacibasi Foundation, Turkey, and Alan J. Gebhart Prize in Excellence in Neuropathy Research (2022) by the Peripheral Nerve Society. He is an Ex-Officio member of the Board of Directors of the American Neurological Association, and Vice-President of the Toxic Neuropathy Consortium. He serves on several editorial boards and is the Editor-in-Chief of Annals of Clinical and Translational Neurology. Dr. Hoke is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Wallerian Degeneration, Peripheral Neuropathy, Tomaculous Neuropathy, Spinal Muscular Atrophy with Arthrogryposis, and Prostatectomy.

Dr. Alexander Pantelyat cares for patients with movement disorders such as Parkinson's disease and related syndromes, essential tremor, dystonia, chorea and normal pressure hydrocephalus. He also provides botulinum toxin injections for movement disorders and is involved in deep brain stimulation programming and intraoperative neurophysiological monitoring.His research explores atypical parkinsonian disorders, such as dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome/degeneration and multiple system atrophy; cognitive aspects of movement disorders; and music-based rehabilitation of neurodegenerative diseases.Dr. Pantelyat earned his medical degree from Temple University School of Medicine in Philadelphia, where he was elected a member of the Alpha Omega Alpha Honor Medical Society and received the Matthew T. Moore Prize in Neurology. He completed his residency training in Neurology ​at the University of Pennsylvania in Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania/Philadelphia VA Medical Center. As part of his fellowship, Dr. Pantelyat also completed the Clinical Research Certificate Program at the Center for Clinical Epidemiology and Biostatistics. He is a 2013 American Academy of Neurology Palatucci Advocacy Leader and grant recipient. Dr. Pantelyat is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration.

Dr. Tom Crawford has been a member of the Department of Neurology since 1987. He is co-director of the MDA clinic for Neuromuscular Disorders and Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins. His practice involves general child neurology with a principal interest in caring for children with neuromuscular, neuromotor, and ataxic disorders. Primary research interests involve the basic science and clinical characterization of two important neurologic disorders that affect children: Spinal Muscular Atrophy and Ataxia Telangiectasia. He is also actively involved in the Biology of neurofilaments by characterization of transgenic animal models. He is on the Medical and Scientific Advisory Boards of Families of Spinal Muscular Atrophy, and the Medical Advisory Committee for the Muscular Dystrophy Association. He is the Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins, which has evaluated almost half of the known patients with this disorder in the United States. Additional specific clinical interests include evaluation and treatment of children with brachial plexus palsies. Dr. Crawford received his medical degree from the University of Southern California. He completed a pediatric internship and residency at the Pediatric Pavilion of the Los Angeles County / University of Southern California Medical Center, followed by a pediatric chief residency. He completed his training in Neurology with Special Qualification in Child Neurology at the Los Angeles Childrens Hospital. He then traveled east to the laboratory of Dr John Griffin at Johns Hopkins for a fellowship in Neuromuscular Disorders. Prior to medical training and Neurology residency, he majored in Psychology and Religion at Yale College. Dr. Crawford has published extensively and presented nationally and internationally. He has an active role in teaching medical students and residents in neurology. In addition, Dr. Crawford has special interest and experience in EMG studies of children and adults. Dr. Crawford is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Ataxia-Telangiectasia, and Spinal Muscular Atrophy Type 2.

Dr. Habela completed a Medical Scientist Training Program at the University of Alabama, Birmingham. She received her PhD in Neurobiology in 2008 and her MD in 2010. After medical school, she specialized in child neurology, and completed 2 years of pediatrics residency and 3 years of child neurology residency at the Johns Hopkins Hospital in 2015. She then completed another 2 years of training specifically focused on the diagnosis, characterization and medical and surgical management of patients with epilepsy during an Epilepsy Fellowship at Johns Hopkins. Dr. Habela’s clinic specializes in pediatric neurology and epilepsy. Her clinical focus in on the care of patients with severe epilepsy with or without other neurodevelopmental disorders that have not been easily controlled with medications. She is also focused on the genetic causes of epilepsy and other neurodevelopmental disabilities with the hope that increasing our understanding of the genetic causes of epilepsy and neurodevelopmental disabilities will improve treatment. Dr. Habela’s basic science research is focused on the genetic mechanisms regulating appropriate proliferation, migration and integration of neurons and glial cells in both the prenatal and postnatal developing brain and how aberrations in these processes result in neurodevelopmental disabilities. Her hypothesis is that deregulation of pre and postnatal neurogenesis and synaptogenesis contributes to the behavioral phenotypes observed in many forms of intellectual disability, epilepsy and autism. Her research applies what we know from human genetic studies to basic science studies examining how specific genetic changes alter neurogenesis, synaptogenesis and overall excitation / inhibition balance in laboratory model systems. Her goal is to provide a better understanding of the molecular mechanisms of these processes and, in turn, possibly identify specific targets for disease modifying treatments for epilepsy. Contact for Research Inquiries 600 N. Wolfe Street Meyer 2-147 Baltimore, MD 21287 Phone: (410) 955-9100. Dr. Habela is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her top areas of expertise are 15q11.2 Microdeletion, Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, and Endovascular Embolization.

Dr. Chua is an assistant professor in the Department of Neurology and Division of Movement Disorders at Johns Hopkins. He received his training at the University of Michigan, where he obtained medical and graduate degrees, then completed a residency in neurology and a combined clinical/research fellowship in movement disorders and neurodegeneration. Dr. Chua’s primary research interests are in neurodegenerative disease with a special focus on autophagy — an essential housekeeping process in cells that is particularly important for the health of neurons. Autophagy may provide a way to break down the buildup of toxic proteins found in neurodegenerative diseases, thereby forming the basis of new treatment strategies for these incurable conditions. He has received multiple research grants to support his work, including from the National Institute of Neurological Disorders and Stroke and the American Academy of Neurology (AAN). He is the primary author and co-author of multiple peer-reviewed scientific publications and online learning modules as part of the AAN. Dr. Chua is a contributing author to The Little Black Book of Neurology by Osama Zaidat, Alan Lerner and J. Douglas Miles, and he has been a peer reviewer for the scientific journals Autophagy, eLife and Neurobiology of Disease. He currently serves on the scientific advisory board for the Don't Forget Morgan Foundation, a private organization supporting research and outreach regarding the disease beta-propeller protein-associated neurodegeneration (BPAN). For more information about the Chua Lab, please visit https://chualab.jhmi.edu. Dr. Chua is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Primary Lateral Sclerosis, Parkinson's Disease, Movement Disorders, and Camptocormism.

Mfon Umoh, M.D., Ph.D., is an Assistant Professor in the Division of Geriatric Medicine and Gerontology. Her clinical expertise in geriatric medicine focuses on the diagnosis, treatment, and care for individuals living with dementia and older adults experiencing cognitive decline. Dr. Umoh earned her MD and PhD in Neuroscience from Emory University. She completed her residency in Internal Medicine at Johns Hopkins Bayview Medical Center and her fellowship in Geriatric Medicine at Johns Hopkins University School of Medicine. Dr. Umoh is a K12 Clinical Research Scholar, and a Sarah Miller Coulson Center for Innovative Medicine Human Aging Project and Next Generation Scholar. Her clinical work, research, and teaching centers on improving cognitive outcomes for older adults. Her research focuses on examining biological and social contextual factors that contribute to poor cognitive outcomes for older adults. The goal of her work is to inform clinical care and interventions focused on modifiable risk factors associated with cognitive decline and dementia. Dr. Umoh is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Dementia, and Frontotemporal Dementia.

Dr. Esther Oh is a Professor of Medicine, Psychiatry and Behavioral Sciences and Pathology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise is in evaluation and management of memory disorders. She has an extensive experience in evaluating memory disorders in older adults with multiple chronic diseases, and takes and integrative approach in the treatment of memory disorders. Dr. Oh also serves as the co-director of the Johns Hopkins Memory and Alzheimer’s Treatment Center. Dr. Oh earned her M.D. from the UHS/Chicago Medical School. She completed her residency in internal medicine at the University of Illinois at Chicago where she was a chief resident. She completed a fellowship in geriatric medicine and gerontology at Johns Hopkins University School of Medicine, and received her Ph.D. from the Johns Hopkins Bloomberg School of Public Health. Dr. Oh has received numerous awards including the Merck New Investigator Award, AFAR New Investigator Award in Alzheimer’s disease, and the Johns Hopkins Clinical Research Scholars Award. She is also a recipient of several major grants from the National Institute on Aging (NIA). She has also been honored for her teaching by Excellence in Teaching Award in the Division of Geriatric Medicine and Gerontology in 2013 and 2017. Dr. Oh’s research is primarily focused on Alzheimer’s disease and related disorders. Her current projects include: development of biomarkers for detecting early stages of Alzheimer’s disease; understanding the interrelationship between delirium and Alzheimer’s disease; cognitive changes after surgery; and understanding the role of sensory problems (hearing and vestibular function) in Alzheimer’s disease. Dr. Oh is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her top areas of expertise are Delirium, Alzheimer's Disease, Dementia, Deep Brain Stimulation, and Liver Transplant.

Dr. Abhay Moghekar focuses on disorders of cerebrospinal fluid physiology like normal pressure hydrocephalus, obstructive hydrocephalus, congenital hydrocephalus, pseudotumor cerebri, CSF otorhhea, CSF rhinorrhea, intracranial hypotension due to spinal CSF leaks and peri-operative management of patients undergoing repair of CSF otorrhea and rhinorrhea. His research interests include identifying biomarkers of neurodegenerative disorders including Alzheimer's disease and Normal Pressure Hydrocephalus. Dr. Moghekar is rated as an Advanced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). His top areas of expertise are Increased Intracranial Pressure, Hydrocephalus, Pseudotumor Cerebri Syndrome, Stent Placement, and Gastrostomy.

Dr. Argye Hillis is a professor of Neurology, with joint faculty appointments in Physical Medicine and Rehabilitation and in Cognitive Science. She is also the Sheikh Khalifa Stroke Institute Professor of Acute Stroke Diagnoses and Management. Prior to medical training and neurology residency, Dr. Hillis worked as a speech-language pathologist, and conducted clinical research focusing on understanding and treating aphasia and hemispatial neglect. She has brought these areas of experience to impact on her clinical research in neurology, which involves cognitive and neuroimaging studies of aphasia and hemispatial neglect due to acute stroke and focal dementias. She has published extensively on these topics in journals and textbooks. Dr. Hillis is Associate Editor of Stroke and has served as Associate editor of Brain, Annals of Neurology, Aphasiology, American Journal of Speech-Language Pathology, Neurocase, Cognitive Neuropsychology, and Language and Cognitive Processes and served as co-Editor and Chief of Behavioral Neurology. Dr. Hillis serves as the Executive Vice Chair of the Department of Neurology and the Director of the Cerebrovascular Division of Neurology at Johns Hopkins. Dr. Hillis is rated as an Experienced provider by MediFind in the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). Her top areas of expertise are Primary Progressive Aphasia, Stroke, Frontotemporal Dementia, Thrombectomy, and Gastrostomy.